TRPV4 mutations causing mixed neuropathy and skeletal phenotypes result in severe gain of function.
TRPV4 mutations causing mixed neuropathy and skeletal phenotypes result in severe gain of function.
复制标题
DOI:
10.1002/acn3.51523
复制
发表时间:
2022-03
影响因子:
5.3
通讯作者:
McCray BA
中科院分区:
文献类型:
--
作者:
Taga A;Peyton MA;Goretzki B;Gallagher TQ;Ritter A;Harper A;Crawford TO;Hellmich UA;Sumner CJ;McCray BA
Distinct dominant mutations in the calcium‐permeable ion channel TRPV4 (transient receptor potential vanilloid 4) typically cause nonoverlapping diseases of either the neuromuscular or skeletal systems. However, accumulating evidence suggests that some patients develop mixed phenotypes that include elements of both neuromuscular and skeletal disease. We sought to define the genetic and clinical features of these patients. We report a 2‐year‐old with a novel R616G mutation in TRPV4 with a severe neuropathy phenotype and bilateral vocal cord paralysis. Interestingly, a different substitution at the same residue, R616Q, has been reported in families with isolated skeletal dysplasia. To gain insight into clinical features and potential genetic determinants of mixed phenotypes, we perform in‐depth analysis of previously reported patients along with functional and structural assessment of selected mutations. We describe a wide range of neuromuscular and skeletal manifestations and highlight specific mutations that are more frequently associated with overlap syndromes. We find that mutations causing severe, mixed phenotypes have an earlier age of onset and result in more marked elevations of intracellular calcium, increased cytotoxicity, and reduced sensitivity to TRPV4 antagonism. Structural analysis of the two mutations with the most dramatic gain of ion channel function suggests that these mutants likely cause constitutive channel opening through disruption of the TRPV4 S5 transmembrane domain. These findings demonstrate that the degree of baseline calcium elevation correlates with development of mixed phenotypes and sensitivity to pharmacologic channel inhibition, observations that will be critical for the design of future clinical trials for TRPV4 channelopathies.
登录
查看更多内容
影响因子:
2
作者:
Weinstein, Michael M.;Kang, Taekyu;Lachman, Ralph S.;Bamshad, Michael;Nickerson, Deborah A.;Krakow, Deborah;Cohn, Daniel H.
通讯作者:
Cohn, Daniel H.
影响因子:
3
作者:
Goyal, Navin;Skrdla, Pete;Cheriyan, Joseph
通讯作者:
Cheriyan, Joseph
影响因子:
2.2
作者:
Fiorillo, Chiara;Moro, Francesca;Bruno, Claudio
通讯作者:
Bruno, Claudio
影响因子:
9.9
作者:
Chen, D. -H.;Sul, Y.;Bird, T.
通讯作者:
Bird, T.
影响因子:
--
作者:
DELONG, R;SIDDIQUE, T
通讯作者:
SIDDIQUE, T